2.4.0.84010 - Disclosure - Organization and Business Activities (Details)truefalsefalse1false truefalseD2012Q2_M0409_VancocinMemberhttp://www.sec.gov/CIK0000946840duration2012-04-08T00:00:002012-04-09T00:00:00falsefalseVancocinus-gaap_ProductOrServiceAxisxbrldihttp://xbrl.org/2006/xbrldivphm_VancocinMemberus-gaap_ProductOrServiceAxisexplicitMemberItemStandardhttp://www.viropharma.com/20130630itemvphm02false truefalseD2011Q4_M1214_VancocinMemberhttp://www.sec.gov/CIK0000946840duration2011-12-13T00:00:002011-12-14T00:00:00falsefalseVancocinus-gaap_ProductOrServiceAxisxbrldihttp://xbrl.org/2006/xbrldivphm_VancocinMemberus-gaap_ProductOrServiceAxisexplicitMember3false truefalseD2012Q2_M06_VancocinMemberhttp://www.sec.gov/CIK0000946840duration2012-06-01T00:00:002012-06-30T00:00:00falsefalseVancocinus-gaap_ProductOrServiceAxisxbrldihttp://xbrl.org/2006/xbrldivphm_VancocinMemberus-gaap_ProductOrServiceAxisexplicitMemberItemStandardhttp://www.viropharma.com/20130630itemvphm04false truefalseD2013Q2YTD_VancocinMemberhttp://www.sec.gov/CIK0000946840duration2013-01-01T00:00:002013-06-30T00:00:00falsefalseVancocinus-gaap_ProductOrServiceAxisxbrldihttp://xbrl.org/2006/xbrldivphm_VancocinMemberus-gaap_ProductOrServiceAxisexplicitMemberItemStandardhttp://www.viropharma.com/20130630itemvphm0PureStandardhttp://www.xbrl.org/2003/instancepurexbrli05false truefalseD2011Q3_M09_MaximumMember_BuccolamMemberhttp://www.sec.gov/CIK0000946840duration2011-09-01T00:00:002011-09-30T00:00:00falsefalseBuccolamus-gaap_ProductOrServiceAxisxbrldihttp://xbrl.org/2006/xbrldivphm_BuccolamMemberus-gaap_ProductOrServiceAxisexplicitMemberfalsefalseMaximumus-gaap_RangeAxisxbrldihttp://xbrl.org/2006/xbrldius-gaap_MaximumMemberus-gaap_RangeAxisexplicitMember6false truefalseD2011Q3_M09_MinimumMember_BuccolamMemberhttp://www.sec.gov/CIK0000946840duration2011-09-01T00:00:002011-09-30T00:00:00falsefalseBuccolamus-gaap_ProductOrServiceAxisxbrldihttp://xbrl.org/2006/xbrldivphm_BuccolamMemberus-gaap_ProductOrServiceAxisexplicitMemberfalsefalseMinimumus-gaap_RangeAxisxbrldihttp://xbrl.org/2006/xbrldius-gaap_MinimumMemberus-gaap_RangeAxisexplicitMember7false truefalseD2012Q2_MaribavirMemberhttp://www.sec.gov/CIK0000946840duration2012-04-01T00:00:002012-06-30T00:00:00falsefalseMaribavirus-gaap_ProductOrServiceAxisxbrldihttp://xbrl.org/2006/xbrldivphm_MaribavirMemberus-gaap_ProductOrServiceAxisexplicitMemberItemStandardhttp://www.viropharma.com/20130630itemvphm01true 3vphm_OrganizationAndBusinessActivitiesLineItemsvphm_falsenadurationfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1falsefalsefalse00falsefalsefalse2falsefalsefalse00falsefalsefalse3falsefalsefalse00falsefalsefalse4falsefalsefalse00falsefalsefalse5falsefalsefalse00falsefalsefalse6falsefalsefalse00falsefalsefalse7falsefalsefalse00falsefalsefalsexbrli:stringItemTypestringfalse0Organization and business activities disclosures2false 4vphm_AgeOfChildrenAndAdolescentsForPurposeOfBeingEligibleForTreatmentvphm_falsenadurationfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1falsefalsefalse00falsefalsefalse2falsefalsefalse00falsefalsefalse3falsefalsefalse00falsefalsefalse4falsefalsefalse00falsefalsefalse5falsefalsefalse0018 yearsfalsefalsefalse6falsefalsefalse003 monthsfalsefalsefalse7falsefalsefalse00falsefalsefalsexbrli:durationItemTypenaRepresents the age of prolonged, acute, convulsive seizures in infants, toddlers, children and adolescents for the purpose of being eligible for treatment under Centralized Pediatric Use Marketing Authorization.No definition available.false0Age of children and adolescents for the purpose of being eligible for treatment3false 4vphm_NumberOfAdditionalYearsOfExclusivityNotQualifiedvphm_falsenadurationfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1falsefalsefalse00falsefalsefalse2falsefalsefalse003 yearsfalsefalsefalse3falsefalsefalse00falsefalsefalse4falsefalsefalse00falsefalsefalse5falsefalsefalse00falsefalsefalse6falsefalsefalse00falsefalsefalse7falsefalsefalse00falsefalsefalsexbrli:durationItemTypenaRepresents the number of additional years of exclusivity that will not be qualified.No definition available.false0Additional years of exclusivity not qualified4false 4vphm_NumberOfAbbreviatedNewDrugApplicationsApprovedvphm_falsenadurationfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1truefalsefalse33falsefalsefalse2falsefalsefalse00falsefalsefalse3truefalsefalse44falsefalsefalse4falsefalsefalse00falsefalsefalse5falsefalsefalse00falsefalsefalse6falsefalsefalse00falsefalsefalse7falsefalsefalse00falsefalsefalsexbrli:integerItemTypeintegerRepresents the number of abbreviated new drug applications approved.No definition available.false256Number of ANDAs approved5false 4vphm_RoyaltiesObligatedToPayAsPercentageOfNetSalesYearOneAfterApprovalvphm_falsenadurationfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1falsetruefalse00falsefalsefalse2falsetruefalse00falsefalsefalse3falsetruefalse00falsefalsefalse4truetruefalse0.100.10falsefalsefalse5falsetruefalse00falsefalsefalse6falsetruefalse00falsefalsefalse7falsetruefalse00falsefalsefalsenum:percentItemTypepureRepresents the royalties obligated to be paid as a percentage of net sales in year one after approval of the sNDA.No definition available.false0Royalties obligated to be paid as percentage of net sales in year one after approval of sNDA6false 4vphm_RoyaltiesObligatedToPayAsPercentageOfNetSalesYearTwoAfterApprovalvphm_falsenadurationfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1falsetruefalse00falsefalsefalse2falsetruefalse00falsefalsefalse3falsetruefalse00falsefalsefalse4truetruefalse0.100.10falsefalsefalse5falsetruefalse00falsefalsefalse6falsetruefalse00falsefalsefalse7falsetruefalse00falsefalsefalsenum:percentItemTypepureRepresents the royalties obligated to be paid as a percentage of net sales in year two after approval of the sNDA.No definition available.false0Royalties obligated to be paid as percentage of net sales in year two after approval of sNDA7false 4vphm_RoyaltiesObligatedToPayAsPercentageOfNetSalesYearThreeAfterApprovalvphm_falsenadurationfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1falsetruefalse00falsefalsefalse2falsetruefalse00falsefalsefalse3falsetruefalse00falsefalsefalse4truetruefalse0.160.16falsefalsefalse5falsetruefalse00falsefalsefalse6falsetruefalse00falsefalsefalse7falsetruefalse00falsefalsefalsenum:percentItemTypepureRepresents the royalties obligated to be paid as a percentage of net sales in year three after approval of the sNDA.No definition available.false0Royalties obligated to be paid as percentage of net sales in year three after approval of sNDA8false 4vphm_NumberOfExclusiveRightsToStudiesOfVancocinvphm_falsenadurationfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1falsefalsefalse00falsefalsefalse2falsefalsefalse00falsefalsefalse3falsefalsefalse00falsefalsefalse4truefalsefalse22falsefalsefalse5falsefalsefalse00falsefalsefalse6falsefalsefalse00falsefalsefalse7falsefalsefalse00falsefalsefalsexbrli:integerItemTypeintegerRepresents the number of exclusive rights to studies of Vancocin.No definition available.false256Exclusive rights to studies of Vancocin9false 4vphm_NumberOfIndependentPhase2ClinicalStudiesvphm_falsenadurationfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1falsefalsefalse00falsefalsefalse2falsefalsefalse00falsefalsefalse3falsefalsefalse00falsefalsefalse4falsefalsefalse00falsefalsefalse5falsefalsefalse00falsefalsefalse6falsefalsefalse00falsefalsefalse7truefalsefalse22falsefalsefalsexbrli:integerItemTypeintegerRepresents the number of Phase 2 clinical studies.No definition available.false256Number of Phase 2 clinical studiesfalseOrganization and Business Activities (Details)UnKnownUnKnownUnKnownUnKnowntruefalsefalseSheethttp://www.viropharma.com/role/DisclosureOrganizationAndBusinessActivitiesDetails79